IL-18BP (human) (monomer):Fc (silent) InVivoKine(tm)

AdipoGen Life Sciences

IL-18BP (human) (monomer):Fc (silent) InVivoKine(tm)

10

Research Use Only

1 mg/ml

>95%

IL18BP

interleukin 18 binding protein

FVH, IL18BPa, interleukin-18-binding protein, MC51L-53L-54L homolog gene product, tadekinig-alfa

Interleukin-18-binding protein

IL-18, initially named interferon-gamma inducing factor (IGIF) is an IL-1 family member and a cytokine that links innate and adaptive immunity. Depending on the microenvironment and timing, IL-18 can either drive harmful inflammation or restore immune homeostasis. IL-18 is regulated i) by the inflammasome that converts the inactive pro-IL-18 to its active form IL-18; ii) by the cytokine it induces, the master cytokine IFN-gamma that triggers the expression of the inhibitor of IL-18, called IL-18 binding protein (IL-18BP). IL-18 binding protein (IL-18BP) is one of only four natural cytokine antagonists. IL-18BP has an exceptionally high affinity for IL-18 and its slow dissociation rate makes it an effective regulator of IL-18, essential for maintaining immune balance and influencing disease outcomes. The IL-18BP (human) (monomer):Fc (silent) InVivoKine™ is produced by using two different vectors, one encoding for the IL-18BP (human):Fc (LALA-PG) Knobs sequence (synthesizing a protein of 70kDa) and one encoding for the Fc (LALA-PG) Holes sequence (synthesizing a protein of 28kDa). Both vectors transfected into HEK293 cells produce both Fc molecules (Knobs-into-Holes technology; J.B. Ridgway, et al.; Protein Eng. 9, 617 (1996)) required for dimerization of the Fc moieties and for secretion of the final protein IL-18BP (human) (monomer):Fc (silent) InVivoKine™. The LALA-PG mutations inhibit binding to FcgammaRs and C1q while FcRn binding and Fc stability remain unaffected. InVivoKines™ are a new generation of recombinant fusion proteins for immunotherapeutic, preclinical, and translational in vivo research, developed and manufactured by AdipoGen Life Sciences. - Recombinant Protein. Human IL-18BP (aa 31-194) is fused at the C-terminus to the Fc portion of human IgG1 (LALA-PG) (Knobs-into-Holes technology) (see reference: J.B. Ridgway, et al.; Protein Eng. 9, 617 (1996)). Lyophilized. Contains PBS. IL-18, initially named interferon-gamma inducing factor (IGIF) is an IL-1 family member and a cytokine that links innate and adaptive immunity. Depending on the microenvironment and timing, IL-18 can either drive harmful inflammation or restore immune homeostasis. IL-18 is regulated i) by the inflammasome that converts the inactive pro-IL-18 to its active form IL-18; ii) by the cytokine it induces, the master cytokine IFN-gamma that triggers the expression of the inhibitor of IL-18, called IL-18 binding protein (IL-18BP). IL-18 binding protein (IL-18BP) is one of only four natural cytokine antagonists. IL-18BP has an exceptionally high affinity for IL-18 and its slow dissociation rate makes it an effective regulator of IL-18, essential for maintaining immune balance and influencing disease outcomes. The protein IL-18BP (human) (monomeric):Fc (LALA-PG)-KIH (human) (rec.) is produced by using two different vectors, one encoding for the IL-18BP (human):Fc (LALA-PG) Knobs sequence (synthesizing a protein of 70kDa) and one encoding for the Fc (LALA-PG) Holes sequence (synthesizing a protein of 28kDa). Both vectors transfected into HEK293 cells produce both Fc molecules (Knobs-into-Holes technology; J.B. Ridgway, et al.; Protein Eng. 9, 617 (1996)) required for dimerization of the Fc moieties and for secretion of the final protein IL-18BP (human) (monomeric):Fc-KIH (human) (rec.). The LALA-PG mutations inhibit binding to FcgammaRs and C1q while FcRn binding and Fc stability remain unaffected. InVivoKines™ are a new generation of recombinant fusion proteins for immunotherapeutic, preclinical, and translational in vivo research, developed and manufactured by AdipoGen Life Sciences.

-20°C,2°C to 8°C

41116120

Human